Navigation Links
Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH

AMSTERDAM, November 23 /PRNewswire/ -- Kiadis Pharma announces today that there will be three presentations on its products ATIR and Rhitol in poster sessions at the 2007 Annual Meeting of the American Society of Hematology (ASH) December 8-11 in Atlanta, Georgia, USA. Data will be presented from the companies ongoing clinical study on ATIR by its principal investigator Dr. Denis Claude Roy, who also presents data on the functionality of Rhitol. In addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the NIH.

ATIR: presentation of clinical phase I/II study on mismatched transplantations by Dr. Denis-Claude Roy

Title poster: "Phase I/II clinical trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher doses of Donor Lymphocyte Infusions depleted of Alloreactive Cells using ATIR may improve outcome without causing GvHD

- Abstract #2976; Poster 2976, Board #195-III (10 December,5-7 pm)

Dr. Denis Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "Our results indicate that the post-transplant infusion of a ATIR-PDT treated DLI is feasible, does not induce acute GVHD, and suggests a clinical benefit for patients receiving the highest DLI doses to accelerate T cell reconstitution. This PDT strategy represents an appealing alternative for older patients and those at high risk for GVHD"

Rhitol: presentation on functionality of Rhitol in chronic GvHD by Dr. Denis-Claude Roy

Title poster: " anti-Chronic Graft Versus Host Disease activity through a regulatory T Cell dependent mechanism after photodynamic therapy.

- Abstract #3280; Poster 3280; Board #499-III (10 December,5-7 pm)

Dr. Denis-Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "our results demonstrate that TH9402 PDT not only eliminates activated T cells, but preserves Tregs, with the functional ability to inhibit residual alloreactive cGVHD cells. This inhibitory effect requires live effector Tregs, secretion of IL-10 and TGF-β expression. With such dual effector mechanisms, photopheresis using TH9402 should translate into improved treatment efficacy and enhanced quality of life for patients with chronic GVHD"

Presentation of independent NIH study of Kiadis Pharma product ATIR Dr. Stephan Mielke

Title poster: "Successful Translation of a GMP-Based, Clinical Scale Selective Allodepletion Approach for Matched Donor-Recipient Pairs from Bench-to-Bedside"

- Abstract #3279; Poster 3279, board #499-III (10 December, 5-7 pm)

For the complete press release go to: _a t_ASH/33

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists)

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: